Corbus Pharmaceuticals Revenue, Profits - CRBP Quarterly Income Statement

Add to My Stocks
$7.95 $2.77 (53.47%) CRBP stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the Corbus Pharmaceuticals stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. Like any other income statement, the CRBP income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of 0 when compared to the same period in the past. Revenue for year 2018 Q2 is $- and has decreased from $- quarter on quarter as is evident when you compare the latest figures in the latest Corbus Pharmaceuticals profit and loss statement with those of the prior corresponding period. Also see Corbus Pharmaceuticals assets and Corbus Pharmaceuticals free cash flow for a complete valuation of CRBP stock.

View and download details of revenue and profits for Corbus Pharmaceuticals for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Corbus Pharmaceuticals Revenues or Net Sales
-----1.29M----
Cost Of Goods Sold (COGS)----------
Corbus Pharmaceuticals Gross Profit
-----1.29M----
Research & Development Expense10.26M9.76M8.29M5.62M5.76M6.36M5.39M4.31M3.56M2.17M
Selling General & Admin Expense2.99M3.05M2.58M2.13M1.87M2.38M2.57M1.76M1.02M1.1M
Income Before Depreciation Depletion Amortization-12.39M-11.86M-10.87M-6.95M-7.29M-7.45M-7.58M-5.33M-4.19M-2.88M
Depreciation Depletion Amortization----------
Non Operating Income----0.01M-0.01M-0.01M--0.01M--
Interest Expense-------0.01M---
Corbus Pharmaceuticals Pretax Income
-12.07M-11.69M-10.71M-6.96M-7.29M-7.46M-7.58M-5.34M-4.18M-2.89M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-12.07M-11.7M-10.69M-6.97M-7.3M-7.47M-7.57M-5.35M-4.19M-2.89M
Extraordinary Items & Discontinued Operations----------
Corbus Pharmaceuticals Profit/ Loss (Net Income)
-12.07M-11.7M-10.69M-6.97M-7.3M-7.47M-7.57M-5.35M-4.19M-2.89M
Average Shares used to compute Diluted EPS57.16M56.37M52.88M50.22M50.19M46.38M43.04M43.78M38.75M37.61M
Average Shares used to compute Basic EPS57.16M56.37M52.88M50.22M50.19M46.38M43.04M43.78M38.75M37.61M
Income Before Nonrecurring Items-12.07M-11.7M-10.69M-6.97M-7.3M-7.47M-7.57M-5.35M-4.19M-2.89M
Income from Nonrecurring Items----------
Corbus Pharmaceuticals Earnings Per Share Basic Net
-0.21-0.21-0.20-0.14-0.15-0.16-0.18-0.12-0.11-0.08
Corbus Pharmaceuticals Earnings Per Share Diluted Net
-0.21-0.21-0.20-0.14-0.15-0.16-0.18-0.12-0.11-0.08
EPS Diluted Before Nonrecurring Items-0.21-0.21-0.20-0.14-0.15-0.16-0.18-0.12-0.11-0.08
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Corbus Pharmaceuticals stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q2. Our Corbus Pharmaceuticals revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-12.07M for CRBP stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the CRBP income statement, one can check the Corbus Pharmaceuticals historical stock prices to check how the price has moved with time.

Corbus Pharmaceuticals Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
174.78
Dividend Yield
0%